Alzheimer’s drug Leqembi has full FDA approval now and that means Medicare will pay for it

WASHINGTON — U.S. officials granted full approval to a closely watched Alzheimer's drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.

The FDA confirmed those results by reviewing data from a larger, 1,800-patient study in which the drug slowed memory and thinking decline by about five months in those who got the treatment, compared to those who got a dummy drug. The process of converting a drug to full FDA approval usually attracts little attention. But Alzheimer's patients and advocates have been lobbying the federal government for months after Medicare officials announced last year they wouldn't pay for routine use of Leqembi until it received FDA's full approval.

Medicare administrator, Chiquita Brooks-LaSure, has made clear the program will immediately begin paying for the drug now that it has full FDA approval. But the government is also setting extra requirements. Doctors need to confirm that patients have the brain plaque targeted by Leqembi before prescribing it. Nurses need to be trained to administer the drug and patients must be monitored with repeated brain scans to check for swelling or bleeding. The imaging and administration services carry extra costs for hospitals beyond the drug itself.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
Source: CNBC - 🏆 12. / 72 Read more »

FDA approves Alzheimer’s treatment Leqembi, clearing the way for Medicare coverageDespite Medicare coverage, drug may remain out of reach for many patients, policy experts say
Source: MarketWatch - 🏆 3. / 97 Read more »

FDA Approves Leqembi, Extending Alzheimer’s Treatment to More PatientsThe FDA granted full approval to Alzheimer's drug Leqembi, allowing Medicare enrollees to get fully covered treatment with the drug if they qualify and agree to report data to a registry
Source: WSJ - 🏆 98. / 63 Read more »

Alzheimer’s drug Leqembi granted full FDA approvalUPDATE: U.S. officials granted full approval to a closely watched Alzheimer’s drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.
Source: WTVYNews4 - 🏆 590. / 51 Read more »

Alzheimer’s drug Leqembi receives full FDA approvalThe Food and Drug Administration endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer’s disease. It’s the first medicine that’s been convincingly shown to modestly slow Alzheimer’s cognitive decline.
Source: chicagotribune - 🏆 8. / 91 Read more »

FDA Approves Promising New Alzheimer’s Drug LeqembiNot only is it the first Alzheimer’s antibody treatment to get full FDA approval, it’s also the first that will be broadly covered by Medicare.
Source: thedailybeast - 🏆 307. / 63 Read more »